Lung Care Program
Leveraging the benefit of using ctDNA-based Next-Generation Sequencing (NGS) as a companion tool to conventional methods in ambiguous lung cases.
Program Information
In real-life practice, many CT scans yield ambiguous results, such as small lung nodules classified under LUNG-RADS (1), which might leave clinicians and patients uncertain about the malignancy status and the appropriate follow-up surveillance path. ctDNA screening results can thus support and guide diagnosis and surveillance strategies.
The Lung Care Program provides free SPOT-MAS Lung tests in selected countries and hospitals, empowering doctors to effectively monitor patients with nodules classified as LUNG-RADS.
Name: Lung Care
Launch: 2025
Countries: Singapore, Vietnam, Thailand, Malaysia, Indonesia, Philippines
* Each country is allocated a specific number of free tests, and it will be the doctors who determine which patients are eligible for testing.
SPOT-MAS Lung
A non-invasive blood test to detect cancer early
SPOT-MAS Lung is a cancer screening blood test that integrates a multiomics tumor ATLAS with AI-driven feature engineering and deep learning models to analyze genetic, epigenetic, and fragmentomic data. This methodology offers a precise, non-invasive, and affordable test specifically designed for lung cancer screening. (2)
Only requires a blood draw tube
Next-Generation Sequencing
